- Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
-
Huang CF, Wu PF, Yeh ML, Huang CI, Liang PC, Hsu CT, Hsu PY, Liu HY, Huang YC, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML
- KMID: 2511463
- Clin Mol Hepatol.
- 2021 Jan;27(1):136-143.
- doi: 10.3350/cmh.2020.0150
Background/Aims: Obstacles exist in facilitating hepatitis C virus (HCV) care cascade. To increase timely and accurate diagnosis, disease awareness and accessibility, in-hospital HCV reflex testing followed by automatic appointments and... -
- CITED
-
- Close
- SHARE
-
- Close
- Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognos- tic factor in hepatitis C virus-related hepatocellular carcinoma
-
Lin CC, Liu TW, Yeh ML, Tsai YS, Tsai PC, Huang CF, Huang JF, Chuang WL, Dai CY, Yu ML
- KMID: 2514773
- Clin Mol Hepatol.
- 2021 Apr;27(2):313-328.
- doi: 10.3350/cmh.2020.0247
Background/Aims: Growth hormone (GH) is the main regulator of somatic growth, metabolism, and gender dimorphism in the liver. GH receptor (GHR) signaling in cancer is derived from a large body... -
- CITED
-
- Close
- SHARE
-
- Close
- Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan
-
Huang CF, Dai CY, Lin YH, Wang CW, Jang TY, Liang PC, Lin TC, Tsai PC, Wei YJ, Yeh ML, Hsieh MY, Huang CK, Huang JF, Chuang WL, Yu ML
- KMID: 2560091
- Clin Mol Hepatol.
- 2024 Oct;30(4):883-894.
- doi: 10.3350/cmh.2024.0414
Background/Aims: Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
-
Yuen MF, Chuang WL, Peng CY, Jeng WJ, Su WW, Chang TT, Chen CY, Hsu YC, De La Rosa G, Ahmad A, Luo E, Conery AL
- KMID: 2557390
- Clin Mol Hepatol.
- 2024 Jul;30(3):375-387.
- doi: 10.3350/cmh.2023.0535
Background/Aims: Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells.... -
- CITED
-
- Close
- SHARE
-
- Close
- Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
-
Hsu PY, Wei YJ, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Chuang WL, Huang CF, Chiu YW, Yu ML
- KMID: 2511467
- Clin Mol Hepatol.
- 2021 Jan;27(1):186-196.
- doi: 10.3350/cmh.2020.0180
Background/Aims: Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
-
Hou J, Gane E, Balabanska R, Zhang W, Zhang J, Lim TH, Xie Q, Yeh CT, Yang SS, Liang X, Komolmit P, Leerapun A, Xue Z, Chen E, Zhang Y, Xie Q, Chang TT, Hu TH, Lim SG, Chuang WL, Leggett B, Bo Q, Zhou X, Triyatni M, Zhang W, Yuen MF
- KMID: 2554426
- Clin Mol Hepatol.
- 2024 Apr;30(2):191-205.
- doi: 10.3350/cmh.2023.0422
Background/Aims: Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics... -
- CITED
-
- Close
- SHARE
-
- Close
- Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
-
Lu MY, Huang CF, Hung CH, Tai C, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang S, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin C, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Tsai CW, Chen CY, Yu ML, TACR Study Group
- KMID: 2549384
- Clin Mol Hepatol.
- 2024 Jan;30(1):64-79.
- doi: 10.3350/cmh.2023.0287
Background/Aims: Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to... -
- CITED
-
- Close
- SHARE
-
- Close
